AbbVie Inc., Johnson & Johnson Services, Inc, GlaxoSmithKline plc, are Dominating the U.S. Dermatology Drugs Market in 2019

U.S Dermatology Drugs Market is projected to register a steady CAGR of 8.2% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below:

Access Full Report at https://www.databridgemarketresearch.com/reports/us-dermatology-drugs-market       

U.S dermatology drugs market is a highly consolidated market which includes key players and local players. The market has witnessed increased various strategic developments owing to favourable market scenario.

The market has a prominent growth in upcoming years due to growing demand for the dermatology drugs products, booming across healthcare, technological advancements of U.S dermatology drugs. The market has witnessed developments in terms of product launches to enhance the product portfolio to meet the rising demand of innovative monitoring technology in dermatology drugs. For instance, in March 2019, AbbVie Inc. announced that they have received approval for their SKYRIZI which is a humanized immunoglobulin G1 (IgG1) monoclonal antibody in order to inhibit IL-23 used in the treatment of generalized pustular psoriasis, plaque psoriasis, erythrodermic psoriasis and psoriatic arthritis in Japan. This product launch will help in making treatments to patient worldwide and therefore it enhances AbbVie presence worldwide.  

The major players dealing in the U.S. dermatology drugs market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio.

AbbVie Inc. is the dominating player in the U.S dermatology drugs market and accounts the highest market share in 2019, which is followed by Novartis AG, Pfizer Inc., Eli Lilly and Company., Johnson & Johnson Services, Inc., Almirall, S.A, Mylan N.V., Sun Pharmaceutical Industries Ltd., UCB S.A., Belgium, Glenmark Pharmaceuticals Limited, Tolmar Pharmaceuticals, Inc., GlaxoSmithKline plc., Galderma Laboratories, L.P., Teva Pharmaceutical Industries Ltd., LEO Pharma A/S, MELINTA THERAPEUTICS, INC. - THE ANTIBIOTICS COMPANY, Mayne Pharma Group Limited, BIOFRONTERA AG, among others.  

U.S. Dermatology Drugs Market

AbbVie Inc.

AbbVie Inc. headquartered in Illinois, U.S. was founded in 2013. The company focuses on developing a consistent stream of innovative new medicines, building market leadership and enhancing the culture. AbbVie Inc. has approximately 30,000 employees in the company.

The company is continuously engaged in strategic relationship to enhance the product of the dermatology drugs such as,     

  • In October 2019, AbbVie Inc. announced that they have launched a platform that is Let me be clear about empowering people with psoriasis to speak up and seek freedom from their disease. Through this launch of a platform, AbbVie would get benefits by enhancing its credibility in the market.

The company has its presence in Africa, Asia-Pacific, Europe, Latin America / Caribbean, Middle East, North America, South America. The company has various subsidiaries such as Pharmacyclics (U.S.), Stemcentrx, Inc. (U.S.), MavupharmaInc. (U.S.), Abbott Bioresearch Center, Inc (U.S.), Kos Pharmaceuticals (U.S.), and Abbott Endocrine Inc (U.S.) among others.

Johnson & Johnson Services, Inc.

Johnson & Johnson Services, Inc. headquartered in New Jersey, U.S. was founded in 1886. The company is engaged in the research and development, manufacturing and sale of a wide range of products in the health care field. It has 135,100 employees in the company. The company has multiple business segments such as pharmaceutical, medical devices, and consumer. The company has wide range of product category such as consumer health products, medical devices and pharmaceutical products.      

The company is continuously engaged in strategic relationship to enhance the product of the dermatology drugs such as     

  • In October 2019, The Janssen pharmaceutical companies of Johnson & Johnson Services, INC. received FDA approval for their product Stelara, which is used in the treatment of adult patients suffering from slightly to severely active ulcerative colitis. After receiving FDA approval, the company commercialized their product into the market.   

The company has its presence in Europe, Asia-Pacific, Middle East & Africa and Americas. The company has subsidiaries such as Unilever Johnson & Johnson Vision Care, Inc. (U.S.), Neutrogena (U.S.), DePuySynthes (U.S.), Ethicon USA, LLC. (U.S.), Janssen Global Services, LLC (Belgium) among others.   

GLAXOSMITHKLINE PLC.

GLAXOSMITHKLINE PLC headquartered in Brentford, U.K. was founded in 1715. The company has 95,490 employees in the company. The company is focused in the innovation, development, manufacturing and marketing of vaccines, pharmaceutical products, health-related consumer products and over-the-counter medicines. The company has multiple business categories such as pharmaceuticals, consumer health and vaccines. The company has various product categories such as prescription medicines, our vaccines, our consumer healthcare products, viivviivhealthcare, stiefeldermatology.   

The company has presence in Africa, Asia & the Middle East, Australasia, Europe, North America, South & Central America. The company has various subsidiaries such as Adriatic Acquisition Corporation (U.S.), Allen PharmazeutikaGesellschaftm.b.H. (Austria), Barrier Therapeutics, Inc (U.S.), Block Drug Company, Inc. (U.S.), CascanGmbH & Co. KG (Germany) among others.